Subscribe

What are you looking for?

Main Menu

明報新聞網

中生製藥：與阿斯利康就TQC3721訂立獨家授權協議 最高可達19億美元

Future Wealths
Future Wealths
8 7 月, 2026
One Min Read
1 Views
0 Comments
中生製藥(1177)公布，集團附屬公司正大天晴已與阿斯利康就集團自主研發的PDE3/4抑制劑（研發代號：TQC3721）訂立獨家授權協議。

原文: https://finance.mingpao.com/fin/instantf/20260708/1783476396302/%E4%B8%AD%E7%94%9F%E8%A3%BD%E8%97%A5-%E8%88%87%E9%98%BF%E6%96%AF%E5%88%A9%E5%BA%B7%E5%B0%B1tqc3721%E8%A8%82%E7%AB%8B%E7%8D%A8%E5%AE%B6%E6%8E%88%E6%AC%8A%E5%8D%94%E8%AD%B0-%E6%9C%80%E9%AB%98%E5%8F%AF%E9%81%9419%E5%84%84%E7%BE%8E%E5%85%83%22%20target=%22blank

Last Update: 8 7 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept